Vaccines

Real-World Evidence Shows Strong Protection from COVID-19 with J&J Vaccine and Booster

September 23, 2021

New data finds J&J COVID-19 vaccine and booster to provide increased protection against COVID-19.

Pfizer and BioNTech Announce Positive Results In COVID-19 Vaccine Trial for Children Ages 5 to 11

September 21, 2021

The topline data from Pfizer and BioNTech’s trial suggests that a 10 µg vaccine is safe and effective among the 5 to 11 age group.

Vaccine Booster Battle Reveals Rifts Among Regulators and Sponsors

September 20, 2021

FDA advisors agreed unanimously on a more limited booster plan after rejecting Pfizer’s original request to authorize its third shot for everyone over age 16.

Moderna Releases New Clinical Data on COVID-19 Vaccine

September 17, 2021

Moderna’s newest insights include an overall efficacy review, a study on breakthrough infections, and a study on long-term immunity.

Biden Bolsters Vaccine Production in Pandemic Preparedness Plan

September 10, 2021

The White House announced a nearly $3 billion program to ramp up production of vaccines and their components.

Setting a Clear Strategy for Primary Packaging

September 03, 2021

Alternative materials, as well as supply-chain planning, are essential to ensure a reliable supply for parenteral drug packaging.

Getting a Nose for Vaccines

September 03, 2021

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Pfizer Vaccine Approval Key to Boosting Vaccination Rates

August 24, 2021

FDA’s full approval of the Pfizer-BioNTech COVID-19 vaccine raises hopes that this action will help overcome vaccine hesitancy.

FDA Approves First COVID-19 Vaccine from Pfizer-BioNTech

August 24, 2021

FDA approved the Pfizer-BioNTech COVID-19 vaccine, which will be marketed as Comirnaty.

KGI Team Adapts Vaccine Development Work to Address COVID-19

August 12, 2021

A research team at the Keck Graduate Institute will work to adapt its decade-long low-cost vaccine R&D for developing countries into a COVID-19 vaccine.